Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease

Cognition Therapeutics Inc. has announced positive topline results from its Phase 2 SEQUEL study of CT1812 in patients with mild-to-moderate Alzheimer's disease. The study showed a positive treatment effect of CT1812 on global and regional brain activity, as measured by quantitative electroencephalogram (qEEG). The results indicated a reduction in relative theta power and increased connectivity ..